Welcome to our dedicated page for Staar Surg news (Ticker: STAA), a resource for investors and traders seeking the latest updates and insights on Staar Surg stock.
STAAR Surgical Company (NASDAQ: STAA) features prominently in ophthalmic and corporate news due to its focus on implantable intraocular lenses and its role in the vision correction market. Company press releases describe STAAR as the global leader in implantable phakic intraocular lenses, particularly through the EVO family of Implantable Collamer Lenses (EVO ICL) for vision correction, and as a long-standing participant in ophthalmic surgery since 1982.
This news page aggregates coverage related to STAAR’s product developments, strategic decisions, shareholder actions, and governance changes. Recent announcements include the proposed and later terminated merger agreement with Alcon, a series of special meetings and proxy solicitations, and a cooperation agreement with major shareholder Broadwood Partners under which representatives of Broadwood and Yunqi Capital joined STAAR’s Board of Directors. These events illustrate how transaction activity and shareholder perspectives can influence the company’s direction while it continues to operate as a standalone, publicly traded company on Nasdaq.
Readers can expect updates on topics such as merger and acquisition proposals, outcomes of shareholder votes, board appointments, and other material events reported in STAAR’s press releases and related communications. Because STAAR’s core business centers on ophthalmic surgical products like Implantable Collamer Lenses and intraocular lenses, news may also highlight the positioning of its EVO ICL technology and its use in vision correction procedures in markets around the world.
For investors, analysts, and industry observers, following STAA news offers insight into both the company’s ophthalmic product strategy and its evolving governance and ownership dynamics. This page provides a centralized view of those developments as they are reported in official company and market communications.
STAAR Surgical Company (NASDAQ: STAA) hosted a media day in NYC featuring singer Joe Jonas, who shared his positive experience with EVO Visian® Implantable Collamer® Lenses. Since the FDA approval on March 25, 2022, STAAR has focused on educating potential patients about EVO. To enhance visibility, an omni-channel advertising campaign will begin later this month, showcasing Jonas' journey and patient satisfaction. Additionally, certified surgeons are actively promoting EVO on social media, and new patient ambassadors will join in the outreach efforts.
STAAR Surgical Company (NASDAQ: STAA) has partnered with Joe Jonas for a global campaign to promote its EVO Visian® Implantable Collamer® Lenses (EVO), designed to correct myopia and astigmatism. Recently, Jonas underwent the EVO procedure, achieving visual freedom from glasses and contact lenses. The campaign, launching in September 2022, aims to educate Americans about EVO, which has been successfully implanted worldwide and boasts a high satisfaction rate among patients. EVO lenses offer clarity, UV protection, and are removable if needed.
STAAR Surgical Company (NASDAQ: STAA) reported record net sales of $81.1 million for Q2 2022, up 30% from last year. Constant currency net sales reached $84.2 million, showing a 35% increase. The company achieved a gross margin of 78.8% and net income of $0.26 per share, up from $0.17 per share in the prior year. ICL sales, which made up 96% of total sales, increased by 32%. Despite foreign currency headwinds impacting sales by $3.1 million, STAAR reaffirmed its 2022 net sales outlook of approximately $295 million, driven by strong demand for EVO lenses.
STAAR Surgical Company (NASDAQ: STAA) is set to release its Q2 2022 financial results on August 10, 2022, after market close. The company will host a conference call and webcast the same day at 4:30 p.m. Eastern. This conference will cover financial results and operational updates. STAAR has specialized in ophthalmic surgery for over 40 years, marketing foldable implantable lenses, notably the Visian ICL, with over 2 million units sold worldwide.
Summary not available.
STAAR Surgical Company (NASDAQ: STAA) announced record financial results for Q1 2022, with net sales reaching $63.2 million, a 25% increase year-over-year. ICL sales accounted for $58.7 million of this total, marking a 26% growth. The company reported a gross margin of 77.9% and net income of $9.6 million ($0.19 per share), up from $5.0 million ($0.10 per share) a year earlier. STAAR also highlighted strong global growth, particularly in China, Japan, and India, and reaffirmed its annual sales outlook of approximately $295 million, a 28% increase from the previous year.
STAAR Surgical Company (NASDAQ: STAA) will announce its financial results for Q1 ending April 1, 2022, on May 4, 2022, post-market close. A conference call is scheduled for the same day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss the results. Participants can join by dialing 844-200-6205 (domestic) or 929-526-1599 (international). A replay of the call will be available for seven days after the event. STAAR specializes in implantable lenses and has successfully implanted over 1,000,000 Visian ICLs across more than 75 countries.
STAAR Surgical Company (NASDAQ: STAA) announces the first implants of the EVO Visian® Implantable Collamer® lens (EVO ICL) in the U.S. following product approval. Procedures are set to occur in states including California, Colorado, Missouri, Texas, and Utah. The company also shared its agenda for the ASCRS Annual Meeting in Washington, D.C., from April 22-26, featuring educational events and clinical sessions. President Caren Mason emphasized the U.S. market's significance, representing over 20% of global refractive procedures, and highlighted the excitement around the EVO ICL presentations.
STAAR Surgical has received FDA approval for its EVO/EVO+ Visian® Implantable Collamer® Lens, aimed at correcting myopia and myopia with astigmatism. This innovative lens addresses the growing myopia epidemic, with 100 million U.S. adults aged 21-45 as potential candidates. Over one million EVO lenses have been implanted globally, achieving a 99.4% patient satisfaction rate. With commercialization commencing immediately, this marks a significant step for STAAR in expanding its market presence and addressing the needs of patients seeking alternatives to glasses and contacts.
STAAR Surgical Company (NASDAQ: STAA) reported a strong performance for Q4 and FY 2021, with net sales reaching $59 million for Q4, a 28% increase year-over-year, and full-year sales at $230.5 million, up 41%. Key drivers included a 33% rise in ICL sales and a gross margin increase to 76.3%. Despite challenges due to Covid-19, demand remains robust, especially in China. Net income for Q4 was $4.9 million, or $0.10 per diluted share, compared to $3.3 million a year prior. STAAR projects approximately $295 million in net sales for FY 2022, anticipating another record year.